Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Stopped The study is being withdrawn due to the CRADA with the company not being finalized

Conditions

• Mesothelioma
• Malignant Mesothelioma (MM)
• Early-stage Mesothelioma
• Subclinical Mesothelioma
• BRCA1-Associated Protein-1 (BAP1) Mutations
• Early-stage BAP1-associated Malignancies

Interventions

• DRUG: alrizomadlin

Sponsor

National Cancer Institute (NCI)